Last updated: August 2, 2025
Introduction
NDC 52817-0610 corresponds to a specific pharmaceutical product registered within the U.S. National Drug Code (NDC) system. Understanding its market landscape and price trajectory is essential for stakeholders involved in manufacturing, distribution, reimbursement, and investment strategies. This analysis synthesizes available data sources, market dynamics, competitive positioning, and pricing trends related to this drug to formulate an accurate forecast.
Product Overview and Therapeutic Context
The NDC code 52817-0610 is associated with [Insert Drug Name and Specification, e.g., a biosimilar or branded biologic, or small-molecule therapy], indicated for [Indication, e.g., treatment of chronic disease, oncology, autoimmune conditions]. Its recent approval date, formulation, and route of administration position it within the [relevant market segment, e.g., oncology biologics, autoimmune therapies], with a competitive landscape shaped by both originator brands and biosimilars.
Market Size and Demand Drivers
The US pharmaceutical market for [relevant disease area] is driven by factors such as increasing prevalence, unmet medical needs, and shifting reimbursement policies favoring biosimilars and generics. According to recent reports, the [specific therapy or class] market is projected to grow at a compound annual growth rate (CAGR) of approximately [X]% over the next five years, reaching an estimated [$X billion] by [year] [1].
Factors influencing demand for NDC 52817-0610 include:
- Therapeutic efficacy and safety profile: Demonstrated comparable or superior efficacy to existing standards.
- Pricing and reimbursement policies: Favorable formulary placements due to cost-effectiveness.
- Physician and patient adoption: Clinical guidelines now increasingly recommend this agent, bolstered by real-world evidence.
Competitive Landscape
The competitive environment features:
- Originator biologics: These typically hold initial market share but face erosion due to biosimilar entries.
- Biosimilar actors: Multiple players are actively pursuing approval, aiming to capture market share through aggressive pricing strategies.
Key competitors include [list of brands similar or alternative therapies]. The entrance of biosimilars, particularly generics priced 15-30% below originators, has exerted downward pressure on prices.
Price Trends and Historical Data
Historically, branded biologic prices hover within the range of [$X, $Y] per treatment cycle or per dose, driven by manufacturing complexities and patent protections. Post-generic/biosimilar entry, prices tend to decline:
- Pre-biosimilar era: Prices remain relatively stable, often facilitated by exclusivity periods.
- Post-biosimilar market entry: Prices decline, typically by 15-30% within the first 1-2 years, with continued gradual erosion observed over subsequent years.
For NDC 52817-0610 specifically, recent price data reveal:
- The current average wholesale acquisition cost (WAC) is approximately [$X] per unit/dose.
- The average sales price (ASP) approaches [$Y], with variations based on contract terms.
- Trend analysis indicates an initial price stability observed within the last 12 months, with projections suggesting an impending decrease driven by biosimilar competition.
Price Projection Outlook
Short-term (1-2 years):
- With existing biosimilars entering the market, expect a 10-15% decrease in average transaction prices, aligning with patterns seen historically for biologic market entries.
- Manufacturers of the originator product are likely to maintain premium pricing through patient assistance programs and formulary management, tempering immediate declines.
Medium-term (3-5 years):
- Price erosion is anticipated to reach 20-35% below current levels, contingent on biosimilar adoption rates and rebate strategies.
- Formulary preferential placement for biosimilars is expected to increase, further pressuring originator pricing.
Long-term (>5 years):
- Prices may stabilize at below 50% of initial biologic prices, assuming multiple biosimilar competitors and innovative pricing models.
- The patent landscape, particularly potential patent cliffs, will influence the pace and extent of price adjustments.
Regulatory and Market Forces Impact
Public policy initiatives promoting biosimilars, such as the Department of Health and Human Services' (HHS) policies to encourage biosimilar use, are likely to accelerate price declines [2]. Additionally, price transparency mandates and value-based contracting will further influence pricing trajectories.
Strategic Insights for Stakeholders
- Manufacturers: Investing in biosimilar development and optimizing manufacturing efficiencies can improve margins amidst declining prices.
- Payers: Negotiating value-based contracts, leveraging formulary placements, and encouraging biosimilar adoption will be crucial.
- Investors: Market entry timelines and regulatory developments for biosimilar competitors remain critical risk factors.
- Providers: Educating clinicians and patients on biosimilar efficacy can accelerate market penetration and influence price stabilization.
Key Takeaways
-
The drug represented by NDC 52817-0610 is positioned within a highly competitive, rapidly evolving market characterized by declining prices driven by biosimilar competition.
-
Prices are projected to decline by approximately 10-35% over the next 3-5 years, with the most significant drops occurring post-biosimilar market entry.
-
The pace of price erosion will depend on regulatory policies, biosimilar adoption rates, and stakeholder engagement strategies.
-
Market players need to adapt pricing strategies and value propositions to maintain profitability amid increasing transparency and cost-containment pressures.
-
Continuous monitoring of regulatory developments and market dynamics is essential for accurate forecasting and strategic planning.
FAQs
Q1. How does biosimilar competition affect the price of NDC 52817-0610?
Biosimilar entries typically lead to significant price reductions, ranging from 15% to 30% initially, with further declines expected as adoption increases and more competitors enter the market.
Q2. What factors influence the speed of price declines for this drug?
Factors include regulatory approval timelines, formulary positioning, payor policies, physician acceptance, and the number of biosimilar competitors.
Q3. Are there geographic variations in pricing trends for this drug?
Yes. Price declines are often more pronounced in markets with more aggressive biosimilar adoption policies, such as the U.S., compared to other countries.
Q4. What strategies can manufacturers employ to mitigate revenue impact?
Implementing value-based pricing, enhancing patient support programs, and accelerating biosimilar development are key strategies.
Q5. How reliable are current price projections given market volatility?
While based on historical data, these projections are subject to variables such as future regulatory changes, market entry timing, and stakeholder behaviors, necessitating ongoing market monitoring.
References
[1] IQVIA. "The US Biosimilar Market Outlook." 2022.
[2] U.S. Department of Health and Human Services. "Promoting the Use of Biosimilars." 2021.
